MCL1 and non-small cell lung carcinoma: To investigate whether combination of splicing inhibitor and BCLxL inhibitor would induce cytotoxicity in MCL1-independent NSCLC cells, and to further confirm that BCLxL is the major mediator of synergistic activity, we used a BCLxL-specific inhibitor A1155463 (BCLxL Ki ≤ 0.01 nM)35 for combination studies in the MCL1 low A549 cell line that is cytostatic to E7107 (Figs. 2d and 5b).